Patients who lost massive weight using GLP-1 drugs like semaglutide had better nutritional status and a trend toward fewer complications after abdominoplasty compared to matched patients who lost weight through bariatric surgery.
20% vs 40% complication rateGLP-1 weight loss patients had half the complication rate of bariatric surgery patients after abdominoplasty, though the small sample size (40 total) meant this trend did not reach statistical significance.
What the researchers found
GLP-1 patients had significantly higher albumin (4.0 vs 3.6 g/dL, p=0.021) and prealbumin levels (23.2 vs 18.9 mg/dL, p=0.003) than bariatric surgery patients, indicating superior nutritional status. The overall complication rate trended lower in GLP-1 patients (20% vs 40%, OR 0.38), though this did not reach statistical significance (p=0.301) in this 40-patient study.
After multivariable adjustment controlling for weight loss magnitude, duration, albumin, and pannus weight, the direction of effect continued to favor GLP-1 patients (adjusted OR 0.72, p=0.830). GLP-1 patients had less total weight loss (29.9 vs 47.2 kg, p<0.001), which may partly explain the better outcomes.
Why it matters
The GLP-1 drug revolution is creating an entirely new population of massive weight loss patients seeking body contouring surgery. Unlike post-bariatric patients, these individuals haven't had surgical alteration of their digestive system and may retain better nutritional status. Understanding how this difference affects surgical outcomes is critical for the rapidly growing field of post-GLP-1 body contouring.
How the study worked
This was a retrospective comparative case series conducted from January 2022 to November 2024. Twenty patients who achieved massive weight loss (≥20 kg) through GLP-1 therapy were matched 1:1 with post-bariatric surgery controls by sex, age (±5 years), and postoperative BMI (±3 kg/m²). All patients underwent abdominoplasty. The primary outcome was any complication within 90 days. Multivariable analysis was used to assess the independent effect of weight loss method.
What this study cannot tell us
The sample size was very small (20 per group), making the study underpowered to detect statistically significant differences in complication rates. The retrospective design introduces potential selection bias. GLP-1 patients lost significantly less weight (29.9 vs 47.2 kg), which complicates direct comparison. The study period is relatively short, and long-term outcomes including weight regain and revision rates were not assessed. The study also did not specify which GLP-1 agents were used or their dosing.
How to read the evidence
This is a Level III retrospective comparative case series with a small sample size (40 patients). While the matched design strengthens the comparison, the study is underpowered for its primary endpoint and the retrospective nature introduces potential biases. The findings are hypothesis-generating rather than definitive.
When this study was published
Published in 2025, this is a very recent study addressing an emerging clinical question driven by the rapid adoption of GLP-1 drugs for weight loss. It represents early evidence in what will likely become a major area of plastic surgery research.
The bigger picture
Plastic surgeons are seeing a surge in body contouring consultations driven by GLP-1 drug-induced weight loss. This study is among the first to compare surgical outcomes between these two massive weight loss populations. The superior nutritional profile of GLP-1 patients aligns with the known malabsorptive effects of bariatric surgery, and suggests that body contouring after pharmacologic weight loss may carry a different — potentially lower — risk profile than after surgical weight loss.
Questions still open
- Would complication rate differences reach statistical significance in a larger study, or is the trend primarily driven by the smaller amount of weight loss in GLP-1 patients?
- How do long-term aesthetic outcomes and patient satisfaction compare between the two groups?
- Do GLP-1 patients who lose comparable amounts of weight to bariatric patients (>40 kg) maintain their nutritional advantage?
Common questions
Why might GLP-1 weight loss patients heal better from surgery than bariatric surgery patients?
Is abdominoplasty safe after GLP-1 weight loss?
Read the original research
Abdominoplasty Outcomes after GLP-1 Agonist-Induced versus Post-Bariatric Massive Weight Loss: A Retrospective Comparative Case Series.
Plastic and reconstructive surgery
Citation
Friedman, Or; Tal, Daniel. (2025). Abdominoplasty Outcomes after GLP-1 Agonist-Induced versus Post-Bariatric Massive Weight Loss: A Retrospective Comparative Case Series.. Plastic and reconstructive surgery. https://doi.org/10.1097/PRS.0000000000012523